DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin: In conclusion, we did not observe a significant increase of dysferlin or myogenin in myotubes from a dysferlinopathy patient when treated with EB1089, oprozomib and ixazomib.